New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
07:13 EDTGWPHGW Pharmaceuticals reports promising signs of efficacy, safety in CBD candidate
GW Pharmaceuticals announced physician reports of efficacy and safety data on 27 children and young adults with treatment-resistant epilepsy who have been treated with GW's investigational cannabidiol, or CBD, product candidate, Epidiolex, for a period of 12 weeks. The treatment-resistant patients suffer from a range of epilepsies in which current anti-epileptic drugs have been unsuccessful in adequately controlling seizures, and included such severe forms of epilepsy as Dravet syndrome and Lennox-Gastaut syndrome. Uncontrolled data from two hospital sites in the United States that were generated under expanded access Investigational New Drug applications authorized by the FDA were made available to the company.
News For GWPH From The Last 14 Days
Check below for free stories on GWPH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2014
08:23 EDTGWPHGW Pharmaceuticals mentioned positively at Leerink
Leerink says it has increased confidence in GW Pharmaceuticals' cannabinoid platform after analyzing the clinical potential of GWP42003 for Ulcerative Colitis. The firm believes GWP42003 is being largely overlooked by investors, creating low expectations into the Phase II data. Leerink has an Outperform rating on GW with a $110 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use